| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
As a nutritional supplement and metabolic intermediate, N,N-Dimethylglycine hydrochloride is believed to support energy production, immune function, and cognitive performance. N,N-Dimethylglycine has been investigated for its potential to enhance physical endurance, reduce lactic acid buildup during exercise, and promote overall well-being. It is believed to play a role in metabolic processes, particularly in the synthesis of carnitine and the regulation of homocysteine levels. It is also studied for its potential neuroprotective effects. The compound is potentially useful as a biomarker of protein degradation in COPD patients.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
N,N-Dimethylglycine hydrochloride has been investigated for its potential to enhance physical endurance, reduce lactic acid buildup during exercise, and promote overall well-being. In vitro studies have explored its role in metabolic processes, particularly in the synthesis of carnitine and the regulation of homocysteine levels. It is also studied for its potential neuroprotective effects. The compound is used as a synthetic intermediate in the synthesis of water-soluble prodrug forms of vitamin E and vitamin K1. As a dietary supplement, it is used to improve autism spectrum disorders. |
| ln Vivo |
N,N-Dimethylglycine hydrochloride has been studied as a dietary supplement for improving autism spectrum disorders. It has been investigated for its potential to enhance physical endurance and reduce lactic acid buildup during exercise. In vivo, it is believed to support energy production, immune function, and cognitive performance. The compound plays a role in metabolic processes, particularly in the synthesis of carnitine and the regulation of homocysteine levels.
|
| Enzyme Assay |
Non-cell experimental workflows for N,N-Dimethylglycine hydrochloride typically involve analytical chemistry procedures. The compound is used as a reference standard in HPLC or LC-MS methods for analyzing biological samples. A typical workflow includes preparing standard solutions of N,N-Dimethylglycine hydrochloride at various concentrations, establishing calibration curves, and analyzing samples. Detection is commonly performed using UV absorbance or mass spectrometry. Method validation includes assessment of linearity, precision, accuracy, and recovery.
|
| Cell Assay |
In vitro cell-based experimental workflows for N,N-Dimethylglycine hydrochloride may involve studying its effects on cellular metabolism. Cells are cultured in appropriate medium, treated with varying concentrations of the compound, and analyzed for metabolic markers such as carnitine synthesis or homocysteine levels. Other potential assays might include assessment of cell viability (MTT assay) or measurement of oxidative stress markers.
|
| Animal Protocol |
In vivo animal experimental workflows have been used to study N,N-Dimethylglycine hydrochloride as a dietary supplement. Animal models may be used to assess its effects on physical endurance, cognitive performance, and metabolic parameters. Typical studies involve oral administration of the compound to rodents, followed by measurement of exercise performance, blood metabolite levels, and tissue analysis.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of N,N-Dimethylglycine hydrochloride have been partially characterized. As a water-soluble compound, it is readily absorbed from the gastrointestinal tract and distributed throughout the body. It plays a role in metabolic processes, particularly in the synthesis of carnitine and the regulation of homocysteine levels. The compound is metabolized in the liver and excreted in urine.
|
| Toxicity/Toxicokinetics |
The toxicological data for N,N-Dimethylglycine hydrochloride indicate that it is generally considered to have low toxicity. Standard precautions should be taken when handling any chemical substance. The compound is stable and reactive typical of amino acid derivatives. It is intended for research use and as a dietary supplement.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
See also: N,N-dimethylglycine (with active moiety).
N,N-Dimethylglycine hydrochloride is a versatile compound with significant relevance in both research and health-related applications. It is a natural N-methylated glycine used in comparative analysis with other N-methylated glycines such as sarcosine and betaine. It is a dietary supplement used to improve autism spectrum disorders. It is a synthetic intermediate used in the synthesis of water-soluble prodrug forms of vitamin E and vitamin K1. The compound is not a drug and has not undergone clinical trials for regulatory approval as a pharmaceutical. |
| Molecular Formula |
C4H10CLNO2
|
|---|---|
| Molecular Weight |
139.58
|
| Exact Mass |
139.04
|
| CAS # |
2491-06-7
|
| Related CAS # |
N,N-Dimethylglycine-d6 hydrochloride;347840-03-3;N,N-Dimethylglycine-d3 hydrochloride;1219795-14-8
|
| PubChem CID |
75605
|
| Appearance |
White to off-white solid powder
|
| Density |
1.069g/cm3
|
| Boiling Point |
175.2ºC at 760 mmHg
|
| Melting Point |
189-194 °C(lit.)
|
| Flash Point |
59.8ºC
|
| Vapour Pressure |
0.556mmHg at 25°C
|
| LogP |
0.434
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
70.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)CC(=O)O.Cl
|
| InChi Key |
FKASAVXZZLJTNX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H9NO2.ClH/c1-5(2)3-4(6)7;/h3H2,1-2H3,(H,6,7);1H
|
| Chemical Name |
2-(dimethylamino)acetic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1644 mL | 35.8218 mL | 71.6435 mL | |
| 5 mM | 1.4329 mL | 7.1644 mL | 14.3287 mL | |
| 10 mM | 0.7164 mL | 3.5822 mL | 7.1644 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
